|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0027651,
umls-concept:C0185117,
umls-concept:C0205210,
umls-concept:C0302592,
umls-concept:C0387583,
umls-concept:C0927195,
umls-concept:C1185625,
umls-concept:C1565860,
umls-concept:C1705323,
umls-concept:C2911684
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2002-10-28
|
|
pubmed:abstractText |
This study aims at investigating the relationship between cyclooxygenase-2 expression in tumour vs stroma inflammatory compartment and its possible clinical role. The study included 99 stage IB-IV cervical cancer patients: immunostaining of tumour tissue sections was performed with rabbit antiserum against cyclooxygenase-2. CD3, CD4, CD8, CD25, Mast Cell Tryptase monoclonal antibodies were used to characterise stroma inflammatory cells in nine cervical tumours. An inverse relation was found between cyclooxygenase-2 levels (cyclooxygenase-2 IDV) of tumour vs stroma compartment (r=-0.44, P<0.0001). The percentage of cases showing high tumour/stromal cyclooxygenase-2 IDV ratio was significantly higher in patients who did not respond to treatment (93.3%) with respect to patients with partial (60.5%), and complete (43.7%) response (P= 0.009). Cases with a high tumour/stroma cyclooxygenase-2 IDV ratio had a shorter overall survival rate than cases with a low tumour/stroma cyclooxygenase-2 IDV (P<0.0001). In the multivariate analysis advanced stage and the status of tumour/stroma cyclooxygenase-2 IDV ratio retained an independent negative prognostic role. The proportion of CD3(+), CD4(+), and CD25(+) cells was significantly lower in tumours with high tumour/stroma cyclooxygenase-2 IDV ratio, while a higher percentage of mast cells was detected in tumours showing high tumour/stroma cyclooxygenase-2 IDV ratio. Our study showed the usefulness of assessing cyclooxygenase-2 status both in tumour and stroma compartment in order to identify cervical cancer patients endowed with a very poor chance of response to neoadjuvant therapy and unfavourable prognosis.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/12402155-10384106,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12402155-10605031,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12402155-10728691,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12402155-10841517,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12402155-10917546,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12402155-11371133,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12402155-11457936,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12402155-11466386,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12402155-11668514,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12402155-11830509,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12402155-11830510,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12402155-11844819,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12402155-12181243,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12402155-5910392,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12402155-8164994,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12402155-8521479,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12402155-8941007,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12402155-9247277,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12402155-9630216,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12402155-9870691
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2002 Cancer Research UK
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
4
|
|
pubmed:volume |
87
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1145-52
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12402155-Adult,
pubmed-meshheading:12402155-Aged,
pubmed-meshheading:12402155-Animals,
pubmed-meshheading:12402155-Antigens, CD,
pubmed-meshheading:12402155-Cyclooxygenase 2,
pubmed-meshheading:12402155-Female,
pubmed-meshheading:12402155-Humans,
pubmed-meshheading:12402155-Immunohistochemistry,
pubmed-meshheading:12402155-Immunophenotyping,
pubmed-meshheading:12402155-Isoenzymes,
pubmed-meshheading:12402155-Membrane Proteins,
pubmed-meshheading:12402155-Middle Aged,
pubmed-meshheading:12402155-Neoadjuvant Therapy,
pubmed-meshheading:12402155-Prostaglandin-Endoperoxide Synthases,
pubmed-meshheading:12402155-Rabbits,
pubmed-meshheading:12402155-Stromal Cells,
pubmed-meshheading:12402155-Survival Analysis,
pubmed-meshheading:12402155-Uterine Cervical Neoplasms
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications.
|
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Largo F. Vito, I-00168 Rome, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
